logo
logo

Elpis Biopharmaceuticals Debuts with Series A Funding and Establishment of Scientific Advisory Board

Oct 29, 2020•almost 5 years ago

Round Type

series a

Lexington

Description

Elpis Biopharmaceuticals today announced the closing of a $30 million Series A financing to propel solid tumor and hematological disease therapeutics through pre-clinical studies, which brings the company to a total of $40 million raised including seed funding. The investment is part of a new strategic partnership with a global pharmaceutical company.

Company Information

Company

Elpis Biopharmaceuticals

Location

Lexington, South Carolina, United States

About

Elpis Biopharmaceuticals is developing multifunctional immunotherapies, including dual-targeted armored CAR-T cells and bispecific biologics, aimed at activating the immune system to overcome tumor resistance. Through its proprietary antibody discovery and protein engineering platforms, Elpis is advancing a rich pipeline to treat solid tumors and hematological malignancies with the goal of improving outcomes for patients with difficult-to-treat and resistant cancers. Elpis is headquartered in Lexington, MA, with research labs in the U.S. and China.